230 related articles for article (PubMed ID: 21563232)
1. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
Huang J; Zhang L; Greshock J; Colligon TA; Wang Y; Ward R; Katsaros D; Lassus H; Butzow R; Godwin AK; Testa JR; Nathanson KL; Gimotty PA; Coukos G; Weber BL; Degenhardt Y
Genes Chromosomes Cancer; 2011 Aug; 50(8):606-18. PubMed ID: 21563232
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA alterations in Middle Eastern ovarian cancers.
Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
[TBL] [Abstract][Full Text] [Related]
3. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
Cui W; Cai Y; Wang W; Liu Z; Wei P; Bi R; Chen W; Sun M; Zhou X
J Transl Med; 2014 Jan; 12():10. PubMed ID: 24418330
[TBL] [Abstract][Full Text] [Related]
4. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
[TBL] [Abstract][Full Text] [Related]
5. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
De Marco C; Rinaldo N; Bruni P; Malzoni C; Zullo F; Fabiani F; Losito S; Scrima M; Marino FZ; Franco R; Quintiero A; Agosti V; Viglietto G
PLoS One; 2013; 8(2):e55362. PubMed ID: 23408974
[TBL] [Abstract][Full Text] [Related]
6. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
[TBL] [Abstract][Full Text] [Related]
8. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.
Dobbin ZC; Landen CN
Int J Mol Sci; 2013 Apr; 14(4):8213-27. PubMed ID: 23591839
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
Cheng JC; Auersperg N; Leung PC
Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
[TBL] [Abstract][Full Text] [Related]
10. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
11. Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-Snail signaling pathway.
Yang Y; Zhang J; Zhu Y; Zhang Z; Sun H; Feng Y
Int J Gynecol Cancer; 2014 Nov; 24(9):1564-74. PubMed ID: 25340291
[TBL] [Abstract][Full Text] [Related]
12. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
Carden CP; Stewart A; Thavasu P; Kipps E; Pope L; Crespo M; Miranda S; Attard G; Garrett MD; Clarke PA; Workman P; de Bono JS; Gore M; Kaye SB; Banerji U
Mol Cancer Ther; 2012 Jul; 11(7):1609-17. PubMed ID: 22556379
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Xing M
Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
[TBL] [Abstract][Full Text] [Related]
15. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.
Bellmunt J; Werner L; Leow JJ; Mullane SA; Fay AP; Riester M; Van Hummelen P; Taplin ME; Choueiri TK; Van Allen E; Rosenberg J
PLoS One; 2015; 10(6):e0124711. PubMed ID: 26039708
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
17. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
18. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells.
Fan Y; Wang L; Han X; Liu X; Ma H
Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
20. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]